B.Riley FBR analyst Madhu Kumar maintained a Hold rating on Regulus (NASDAQ: RGLS) today and set a price target of $0.50. The company’s shares closed yesterday at $0.73, close to its 52-week low of $0.61.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 34.4% and a 56.6% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Deciphera Pharmaceuticals Inc, and Clementia Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regulus with a $1.75 average price target.
See today’s analyst top recommended stocks >>
Based on Regulus’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.03 million. In comparison, last year the company had a GAAP net loss of $21.61 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
